Acute Disseminated Encephalomyelitis Following Nivolumab Therapy for Hodgkin Lymphoma: A Case Report and Literature Review Cureus
Clinical psychologist: A Hodgkin lymphoma diagnosis as a young adult changed my life UT MD Anderson
EBV Associated Lymphoma Consortium (EALC) National Cancer Institute (.gov)
Second primary mediastinal grey-zone lymphoma following treatment for classical Hodgkin lymphoma: a rare case report Frontiers
Understanding the Origins of Hodgkin Lymphoma Cells Could Lead to Better Diagnostics WCM Newsroom
Post-Treatment Fertility in Hodgkin Lymphoma Hematology Advisor
Epstein-Barr virus antibodies and risk of non-Hodgkin lymphoma: a pooled analysis of four prospective cohorts Nature
Estrella Immunopharma Activates University Hospitals Cleveland Medical Center as Fourth Clinical Site for Phase I/II STARLIGHT-1 Trial in B-cell Non-Hodgkin’s Lymphoma Business Wire
Hodgkin vs. Non-Hodgkin Lymphoma: How To Tell the Difference health.com
Brown-Shuler to Undergo Treatment for Hodgkin Lymphoma Clemson University Athletics
AZD3470 Displays Clinical Activity in Pretreated Classic Hodgkin Lymphoma CancerNetwork
AZD3470 at ASCO 2026: a promising new drug for Hodgkin lymphoma? Clinical Trials Arena
Ophelia Syndrome: Acute Stupor as a Primary Manifestation of Hodgkin Lymphoma Diagnosed by Fluorodeoxyglucose Positron Emission Tomography Cureus
Transcriptome sequencing of Hodgkin lymphoma Hodgkin and Reed-Sternberg cells reveals escape from NK cell recognition and an unfolded protein response | Blood Cancer Journal Nature
Primary classical Hodgkin lymphoma of breast presenting as recurrent breast abscess in a non-lactating woman: a case report and literature review Frontiers
Pembrolizumab Combo Shows Efficacy in Pediatric High-Risk Hodgkin Lymphoma CancerNetwork
Prevalence, pattern and prognosis of lung lesions in pediatric Hodgkin lymphoma Nature
Outlining Common Drawbacks to Prior Standards for Hodgkin Lymphoma CancerNetwork
Evolution of therapeutic paradigms in Hodgkin lymphoma: from “cure-oriented” to “functional cure” Frontiers
Favezelimab Combo Boosts PFS vs Chemo in PD-1–Refractory Hodgkin Lymphoma CancerNetwork
Evaluation of incidence and outcomes of transformed nodular lymphocyte predominant Hodgkin Lymphoma in the United States: a population-based cohort study Nature
Hodgkin Lymphoma Develops as a Result of Arrested B Cell–Plasma Cell Transition Inside Precision Medicine
7 Signs of Non-Hodgkin Lymphoma You Shouldn’t Ignore Hartford HealthCare
Nivolumab/AVD: A New Standard in Untreated Advanced Hodgkin Lymphoma CancerNetwork
Clinical features, outcomes, and prognostic factors of lymphocyte-depleted classical Hodgkin lymphoma: a population-based SEER analysis Nature
EHA2026 | Congress coverage: Hodgkin lymphoma and T-cell lymphoma Lymphoma Hub
Coexistence of Mycosis Fungoides and Hodgkin Lymphoma in a Pediatric Patient: A Report of a Rare Case Cureus
Advances in lymphoma treatment: new therapies and clinical trials Penn Medicine
Study reveals promising new therapy for non-Hodgkin lymphoma Medical Xpress
Inequities in Access to Rituximab and Survival in Non-Hodgkin Lymphoma: A 20-Year Cohort Study from Nigeria European Society of Medicine
Syncytial Variant of Nodular Sclerosis Classical Hodgkin’s Lymphoma With Hemophagocytic Lymphohistiocytosis: A Rare and Under-Characterized Entity Cureus
Hodgkin’s Lymphoma: Jonathan's Story BMT infonet.org
Delta Goodrem Inspiring Cancer Journey: Hodgkin Lymphoma, Recovery, and Eurovision Return Oncodaily
Nivolumab in Advanced Hodgkin’s Lymphoma The New England Journal of Medicine
Clemson DT to miss 2026 season while undergoing treatment for Hodgkin lymphoma - The Athletic The New York Times
Hodgkin Lymphoma (HL): Microenvironmental Biology Behind a Therapeutic Success Story Oncodaily
Nodular lymphocyte-predominant Hodgkin lymphoma: Leah's story Roswell Park Comprehensive Cancer Center
Evaluation of Baseline and Interim-Therapy PET Features for Prognostication in High-Risk Pediatric Hodgkin Lymphoma: A Retrospective Analysis of the AHOD1331 Trial Journal of Nuclear Medicine
FDA Approves Nivolumab/AVD in Untreated Hodgkin Lymphoma CancerNetwork
Targeting CAR-T cell exhaustion in non-Hodgkin lymphoma: mechanistic insights and emerging clinical strategies Frontiers